late endosomal/lysosomal adaptor, MAPK and MTOR activator 5
RGD ID:
1305005
Description:
Predicted to contribute to guanyl-nucleotide exchange factor activity and molecular adaptor activity. Predicted to be involved in several processes, including positive regulation of interleukin-8 production; positive regulation of intracellular signal transduction; and positive regulation of protein localization to nucleus. Predicted to be located in cytosol. Predicted to be part of FNIP-folliculin RagC/D GAP and Ragulator complex. Predicted to be active in lysosomal membrane. Orthologous to human LAMTOR5 (late endosomal/lysosomal adaptor, MAPK and MTOR activator 5); PARTICIPATES IN mTOR signaling pathway; INTERACTS WITH 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of LAMTOR5 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of LAMTOR5 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of LAMTOR5 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of LAMTOR5 mRNA
MT1 affects the reaction [Copper results in increased expression of LAMTOR5 mRNA] and MT2 affects the reaction [Copper results in increased expression of LAMTOR5 mRNA]
MT1 affects the reaction [Copper results in increased expression of LAMTOR5 mRNA] and MT2 affects the reaction [Copper results in increased expression of LAMTOR5 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of LAMTOR5 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of LAMTOR5 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of LAMTOR5 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of LAMTOR5 mRNA
[Plant Extracts co-treated with Resveratrol] results in decreased expression of LAMTOR5 mRNA and [Plant Extracts co-treated with Resveratrol] results in increased expression of LAMTOR5 mRNA
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in increased expression of LAMTOR5 protein